-
Conditions
Interventions
normal population who doesn'
t have any eye disease and do not use any drug which affected tear film,Glaucoma patienst who use IOP lowering eye drops
Treatment,Treatment
normal subject,glaucoma patients
Sponsors
Faculty of Medicine, Khon Kaen University
Faculty of Medicine,
Khon Kaen University
Eligibility
Sex/Gender
All
Age
20 Years to 90 Years
Inclusion criteria
Inclusion criteria: - Age more than 20 years old - The subjects must be informed consent - Diagnosed as primary open angle glaucoma, pseudoexfoliation glaucoma, pigment dispersion glaucoma, ocular hypertension, chronic angle closure glaucoma or juvenile open angle glaucoma - subjects use IOP lowering agent(s) more than 6 month continuously - subjects don't have any prior glaucoma surgery
Exclusion criteria
Exclusion criteria: - subjects who had undergone any surgery which affect tear film - subjects have eye trauma - subjects who have any of the disease following - Autoimmune disorders . Primary Sjogren syndrome . Secondary Sjogren syndrome associated with rheumatoid arthritis, systemic lupus erythematosus, progressive systemic sclerosis (scleroderma), polymyositis, dermatomyositis, primary biliary cirrhosis . Graft versus host disease . Immune reaction after radiation to head and neck - Infiltrative processes . Lymphoma . Amyloidosis . Hemochromatosis . Sarcoidosis . Infectious process . HIV-diffuse infiltrative lymphadenopathy syndrome . Trachoma - Neuropathic dysfunction . Multiple sclerosis . Cranial neuropathies (Bell’s palsy, vasculitis) . Parkinson disease . Alzheimer disease - Endocrine dysfunction . Androgen deficiency . subject use and drugs that affect tear film - Antihypertensives : clonidine, propanolol - Antidepressants : amitriptyline, nortriptyline, fluoxetine - Benztropine - Antihistamine : diphenhydramine hydrochloride, loratadine, cetirizine, fexofenadine - Marijuana - Thiabendazole - Diphenoxylate hydrochloride - subjects who used artificial tear, cyclosporin eye drop, steroids, topical ocular NSAIDs or autologous serum within 3 months - Subjects who on punctual plug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ocular surface disease severity TBUT, Schirmer test, lissamine green staining score | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between number of eyedrops and ocular surface disease TBUT, Schirmer test, lissamine green staining score,Relationship between duration of medication and ocular surface disease TBUT, Schirmer test, lissamine green staining score,Relationship between number of types of eyedrop and ocular surface disease TBUT, Schirmer test, lissamine green staining score | — |
Countries
Thailand
Contacts
Public ContactPawasoot Supasai
faculty of medicine, Khon Kaen Univesity
Outcome results
None listed